Milam Jami E, Herring-Palmer Amy C, Pandrangi Raj, McDonald Roderick A, Huffnagle Gary B, Toews Galen B
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, USA.
Infect Immun. 2007 Oct;75(10):4951-8. doi: 10.1128/IAI.00176-07. Epub 2007 Jul 23.
C57BL/6 mice develop an allergic bronchopulmonary mycosis following intratracheal inoculation of Cryptococcus neoformans 24067. We determined that only low levels of tumor necrosis factor alpha (TNF-alpha) are produced in the lungs following infection. Thus, the objective of the present studies was to determine whether treatment with a TNF-alpha-expressing adenoviral vector (adenoviral vector with the murine TNF-alpha transgene under the control of the human cytomegalovirus promoter [AdTNFalpha]) could switch the type 2 (T2) T-cell response/T1 T-cell response balance toward the T1 T-cell response. AdTNFalpha induced an increase in TNF-alpha expression at days 3 and 7. At days 7 to 14, the number of cryptococcal lung CFU continued to increase in both untreated and control adenoviral vector (empty adenovirus type 5 backbone)-treated mice, but the number was ultimately 100-fold lower following AdTNFalpha treatment. AdTNFalpha markedly increased neutrophil and macrophage numbers, and pulmonary eosinophilia did not develop. CXCL1, CXCL2, and gamma interferon were also up-regulated, while eotaxin, interleukin-4 (IL-4), and IL-5 were down-regulated. AdTNFalpha treatment also increased the number of CD80(+) and CD40(+) cells and decreased the number of CD86(+) cells (CD11b(+) and CD11c(+)) in the lungs. Major histocompatibility complex class II levels on CD11b(+) cells were increased. Whole-lung expression of inducible nitric oxide synthase was increased, while YM2 expression and acidic mammalian chitinase expression were decreased. None of these effects were observed with the control (empty) adenoviral vector. Overall, these results support the hypothesis that early TNF-alpha expression promotes a shift in T-cell and macrophage polarization from T2/alternatively activated macrophages toward T1/classically activated macrophages, resulting in control of the fungal infection and prevention of the allergic response.
C57BL/6小鼠经气管内接种新型隐球菌24067后会发生过敏性支气管肺真菌病。我们确定感染后肺中仅产生低水平的肿瘤坏死因子α(TNF-α)。因此,本研究的目的是确定用表达TNF-α的腺病毒载体(在人巨细胞病毒启动子控制下带有鼠TNF-α转基因的腺病毒载体[AdTNFα])进行治疗是否能使2型(T2)T细胞应答/T1 T细胞应答平衡转向T1 T细胞应答。AdTNFα在第3天和第7天诱导TNF-α表达增加。在第7至14天,未治疗和用对照腺病毒载体(空的5型腺病毒骨架)处理的小鼠中肺隐球菌CFU数量持续增加,但AdTNFα处理后该数量最终降低了100倍。AdTNFα显著增加中性粒细胞和巨噬细胞数量,且未出现肺嗜酸性粒细胞增多。CXCL1、CXCL2和γ干扰素也上调,而嗜酸性粒细胞趋化因子、白细胞介素-4(IL-4)和IL-5下调。AdTNFα处理还增加了肺中CD80(+)和CD4(+)细胞数量,并减少了CD86(+)细胞(CD11b(+)和CD11c(+))数量。CD11b(+)细胞上的主要组织相容性复合体II类水平增加。肺中诱导型一氧化氮合酶的整体表达增加,而Ym2表达和酸性哺乳动物几丁质酶表达降低。对照(空)腺病毒载体未观察到这些效应。总体而言,这些结果支持以下假设:早期TNF-α表达促进T细胞和巨噬细胞极化从T2/替代性活化巨噬细胞向T1/经典活化巨噬细胞转变,从而控制真菌感染并预防过敏反应。